Handwriting Kinematics Differentiate Cognitive Impairment

• by Kathryn Wighton

• June 1, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

• by Kathryn Wighton

• August 28, 2026

• 2 min

Volatility priors may reveal delusion severity in schizophrenia

Expectations of environmental instability declined alongside delusional symptoms during 6 months following an acute psychotic episode.

• by Andrea Surnit

• August 25, 2026

• 4 min

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

• by Kathryn Wighton

• July 30, 2026

• 5 min